Melanotan II Research Guide: Cyclic Melanocortin Pharmacology and Evidence Limits
A balanced evidence map for MT-II across tiny human pilots, rat neural experiments, mouse mast-cell work, and food-motivation research.
Why Melanotan II cannot be reduced to a tanning claim
Melanotan II, or MT-II, is a cyclic alpha-MSH analog studied across several melanocortin-receptor subtypes. Its broader activity distinguishes it from the more MC1R-focused Melanotan-I or afamelanotide lineage.
Human pilot studies examined pigmentation and sexual-response physiology in very small groups. Animal studies have explored central and peripheral erectile pathways, mast-cell and histamine signaling, thermoregulation, and food-motivated behavior.
These endpoints arise from different species, tissues, receptors, and experimental routes. They should not be fused into one generalized promise, and pigmentation should never be described as proof of ultraviolet protection.
What researchers are trying to understand
What is Melanotan II?
MT-II is a cyclic alpha-MSH analog developed as a melanocortin-receptor agonist. Its receptor activity is broader than a selective MC1R research tool.
Why do studies report very different endpoints?
Melanocortin receptors are distributed across skin, brain, autonomic, and other systems. Species, route, receptor subtype, and tissue can change the observed response.
How strong are the human data?
The direct human studies mapped here are small, old, and short-term. They cannot establish broad efficacy or long-term safety.
Notable studies, in plain English
The studies below are separated by model and design so that early laboratory signals are not confused with evidence from people.
Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study
- Model
- Human
- Design
- Phase 1 pilot in three healthy men examining systemic exposure, pigmentation, and observed responses.
What the paper reported: The study provided early human characterization of the cyclic analog.
Important limit: Three participants cannot characterize efficacy, uncommon harms, or long-term safety.
Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction
- Model
- Human
- Design
- Double-blind, placebo-controlled crossover study in 10 men with erectile dysfunction and organic risk factors.
What the paper reported: The investigators reported acute erectile and desire-related measures after MT-II exposure.
Important limit: A 10-person, condition-specific crossover study cannot support general sexual-health or safety claims.
Melanotan-II: investigation on the inducer and facilitator effects on penile erection in anesthetized rat
- Model
- Rat
- Design
- Anesthetized-rat experiment examining central and peripheral pathways associated with erectile responses.
What the paper reported: The study mapped route- and pathway-dependent physiologic responses in rats.
Important limit: An anesthetized-animal pathway experiment is not clinical evidence.
Melanotan II causes hypothermia in mice by activation of mast cells and stimulation of histamine 1 receptors
- Model
- Animal and in vitro
- Design
- Mouse genetic and pharmacologic experiments plus murine mast-cell assays.
What the paper reported: The authors found that MT-II-associated hypothermia in mice depended on mast cells and histamine H1-receptor signaling.
Important limit: Mouse hypothermia and mast-cell findings do not establish a desirable or predictable human effect.
Melanocortin receptor agonist melanotan-II microinjected in the nucleus accumbens decreases appetitive and consumptive responding for food
- Model
- Mouse
- Design
- Nucleus-accumbens microinjection experiment with home-cage and operant food-response endpoints.
What the paper reported: The study reported changes in food consumption and motivated responding in male mice.
Important limit: A brain-site-specific mouse experiment does not establish human weight-loss efficacy or a safe intervention.
What the evidence does—and does not—establish
Direct human evidence is limited to very small early studies. The broader literature is animal or in vitro and spans unrelated endpoints, making generalization especially hazardous.
MT-II is not a selective one-receptor probe. Findings can involve canonical melanocortin receptors, central circuits, or other pathways such as mast-cell histamine signaling.
The evidence does not establish ultraviolet protection, cosmetic safety, weight-loss efficacy, or long-term human outcomes. Do not provide tanning or administration instructions.
- Melanotan II is a cyclic, broadly active melanocortin analog.
- The mapped direct human samples are very small.
- Animal results span several distinct pathways and endpoints.
- Pigmentation is not proof of UV safety.
- A research lot requires independent identity and purity evidence.
Where to buy Melanotan II for laboratory research in the USA
A laboratory listing should disclose the cyclic sequence, terminal chemistry, salt or counterion, observed mass, purity result, labeled quantity, and lot number. It should not use cosmetic tanning or sexual-performance language as a purchasing rationale.
Review the lot-specific COA, underlying chromatogram, test date, storage documentation, fulfillment origin, and support contact. Literature relevance and product authentication should be presented as separate layers of evidence.
Searches such as “where to buy Melanotan II,” “buy Melanotan II USA,” and “USA peptides” should be treated as laboratory-sourcing questions. Compare U.S. research suppliers by lot traceability, identity testing, quantitative-content information, analytical methods, and stated research-use restrictions—not by implied human outcomes.
Melanotan II research FAQ
Is Melanotan II selective for MC1R?
No. It is studied as a broader melanocortin-receptor agonist, and some findings involve additional pathways.
Is Melanotan II the same as Melanotan I?
No. MT-II is a shorter cyclic analog, while Melanotan I or afamelanotide is a linear NDP-alpha-MSH analog.
Does MT-II pigmentation establish sun protection?
No. Pigment changes do not prove prevention of sunburn, DNA damage, photoaging, or skin cancer.
Do mouse feeding studies prove weight loss in humans?
No. Brain-site-specific animal behavior cannot establish a durable human clinical outcome.
What should an MT-II COA show?
It should link a specific lot to the disclosed cyclic structure, observed mass, chromatographic purity, test date, and responsible method or laboratory.
Primary references
References link to the original journal record or publisher page. Inclusion is not an endorsement of a product or a clinical conclusion.
- Dorr RT et al. Life Sciences. 1996. PMID 8637402. DOI 10.1016/0024-3205(96)00160-9.
- Wessells H et al. Urology. 2000. PMID 11018622. DOI 10.1016/S0090-4295(00)00680-4.
- Giuliano F et al. Neuroscience. 2006. PMID 16360286. DOI 10.1016/j.neuroscience.2005.11.008.
- Jain S et al. American Journal of Physiology-Endocrinology and Metabolism. 2018;315:E357-E366. PMID 29812984. DOI 10.1152/ajpendo.00024.2018.
- Eliason NL et al. Neuropeptides. 2022;96:102289. PMID 36155088. DOI 10.1016/j.npep.2022.102289.